Mergers and acquisitions: Strategic moves forward or frenzies of futile activity?

New biopharmaceutical industry studies shed light on a contentious issue

04-Aug-2005

mergers and acquisitions have driven the concentration process that has both shaped and shaken the biopharmaceutical industry during the past 20 years. The current edition of the Bienentanz Buzz Letter reports on the results of two recent biopharmaceutical industry studies conducted by renowned business academics that have shed new light on M&A. Extensive data was analysed to determine which companies have the tendency to merge and under which conditions those mergers are likely to prove successful in the years to follow. The online newsletter discusses the implications and refers directly to the publications, both of which are currently available for download on the internet.

The Bienentanz Buzz Letter is a life science management newsletter that gets to the core of industry-relevant issues and can be subscribed to free of charge using the Contact-button below.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance